NCI-2022-10661

A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05301842

Clinical Trial Site: Sinai

To see all available clinical trials click here.